Objective: To assess the association between ibuprofen use and the systemic inflammatory biomarkers C-reactive protein (CRP) and interleukin-6 (IL-6) in chronic Spinal Cord Injury (SCI).

Study design: Prospective cohort study.

Setting: Community dwelling individuals with SCI.

Participants: 338 (278 male, 60 female) community dwelling individuals with chronic SCI (≥1-year post-injury).

Interventions: None.

Main outcome measures: CRP and IL-6 levels were quantified by ultra-sensitive ELISA assay. General linear models were used to assess associations between various clinical and demographic factors and CRP and IL-6 levels.

Results: There were 50 active ibuprofen users and 288 non-users. After adjusting for clinical and demographic factors, ibuprofen users had significantly lower CRP levels (2.3 mg/L versus 3.5 mg/L, P = 0.04) and IL-6 levels (3.2 pg/ml versus 4.0 pg/ml, P = 0.04) compared to nonusers.

Conclusions: Our study suggests that self-reported ibuprofen use may be negatively associated with CRP and IL-6 levels in chronic SCI after adjusting for known confounding factors, and suggests ibuprofen use may be an important, potential variable to consider in future studies focused on systemic inflammation in SCI. Future prospective studies require assessing frequency, duration, and dosage-dependent effects of ibuprofen on systemic markers of inflammation in chronic SCI. These findings may support future clinical trials to determine safety and efficacy of ibuprofen treatment for various outcomes in chronic SCI.

目的：评估布洛芬使用与慢性脊髓损伤 (SCI) 中全身炎症生物标志物 C 反应蛋白 (CRP) 和白细胞介素 6 (IL-6) 之间的关联。

研究设计：前瞻性队列研究。

环境：患有 SCI 的社区居民。

参与者： 338 名（278 名男性，60 名女性）患有慢性 SCI（受伤后 1 年以上）的社区居民。

干预：无。

主要结果测量：通过超灵敏 ELISA 测定对 CRP 和 IL-6 水平进行量化。一般线性模型用于评估各种临床和人口统计学因素与 CRP 和 IL-6 水平之间的关联。

结果：布洛芬活跃用户50人，非布洛芬用户288人。调整临床和人口因素后，布洛芬使用者的 CRP 水平（2.3 mg/L 对 3.5 mg/L，P = 0.04）和 IL-6 水平（3.2 pg/ml 对 4.0 pg/ml，P = 0.04）显着降低与非用户相比。

结论：我们的研究表明，在调整已知混杂因素后，自我报告的布洛芬使用可能与慢性 SCI 中的 CRP 和 IL-6 水平呈负相关，并表明布洛芬的使用可能是未来研究中需要考虑的一个重要的潜在变量SCI中的全身炎症。未来的前瞻性研究需要评估布洛芬对慢性 SCI 炎症系统标志物的频率、持续时间和剂量依赖性影响。这些发现可能支持未来的临床试验，以确定布洛芬治疗慢性 SCI 各种结果的安全性和有效性。